No Data
Beijing Aosaikang Pharmaceutical (002755.SZ): Subsidiary Qufu Nucleoside and Pyrimethamine Tablets obtained Pharmaceutical registration certificate.
On January 20, Gelonghui reported that Beijing Aosaikang Pharmaceutical (002755.SZ) announced that its wholly-owned subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd. (hereinafter referred to as "the subsidiary") has recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration for Urokinase and Tepanex tablets. Urokinase and Tepanex tablets are an oral compound nucleoside chemotherapy drug composed of Urokinase and Tepanex in a molar ratio of 1:0.5, suitable for patients who have previously undergone chemotherapy based on fluoropyrimidines, oxaliplatin, and irinotecan, as well as those who have or cannot receive anti-vascular endothelial growth factor (VEGF) treatments.
Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and
Beijing Aosaikang Pharmaceutical (002755.SZ): The application for marketing authorization of the subsidiary Malibavir tablets has been accepted.
On January 3rd, Gelonghui reported that Beijing Aosaikang Pharmaceutical (002755.SZ) announced that its wholly-owned subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd. (referred to as "subsidiary") recently received the acceptance notice for the listing application of Maribavir tablets issued by the National Medical Products Administration. Maribavir is an antiviral drug against human CMV, used for the treatment of cytomegalovirus (CMV) infections and/or diseases following hematopoietic stem cell transplantation or solid organ transplantation, and is intended for adult patients who are refractory to one or more previous treatments (such as Ganciclovir, Valganciclovir, Sidofovir, or Foscarnet) with or without genotype resistance.
Osecon: Report for the third quarter of 2024
beijing aosaikang pharmaceutical (002755.SZ) net income in the third quarter increased by 296.25% year-on-year.
Galunhui October 30th | Beijing Aosaikang Pharmaceutical (002755.SZ) released its third quarter report, with the company achieving revenue of 1.384 billion yuan in the first three quarters, a year-on-year increase of 23.64%; net income of 0.127 billion yuan, a year-on-year increase of 168.79%. In the third quarter alone, revenue reached 0.462 billion yuan, up 13.23% year-on-year; net income was 51.4232 million yuan, up 296.25% year-on-year.
Hong Kong stocks anomaly | Innovent Bio (01801) fell another 10% during the day, reaching a strategic cooperation with Beijing Aosaikang Pharmaceutical, the founder recently reduced holdings by over 0.15 billion Hong Kong dollars of stocks
Innovent Bio (01801) fell by another 10% during the day, as of the time of publication, a decrease of 4.92%, closing at HKD 47.35, with a turnover of 1.627 billion Hong Kong dollars.
